VX16-809-122: A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age with Cystic Fibrosis, Homozygous for F508del

Project: Research project

Project Details

StatusFinished
Effective start/end date8/21/18 → 8/20/21

Funding

  • Vertex Pharmaceuticals Incorporated